U.S. markets closed

Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6100-0.1300 (-3.48%)
At close: 4:00PM EDT

3.6400 +0.03 (0.83%)
After hours: 7:52PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close3.7400
Open3.6900
Bid3.5900 x 900
Ask3.6400 x 2200
Day's Range3.5800 - 3.7300
52 Week Range3.0100 - 15.8900
Volume666,598
Avg. Volume5,531,981
Market Cap72.858M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-1.3370
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%
    Simply Wall St.

    If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%

    Chembio Diagnostics, Inc. ( NASDAQ:CEMI ) has rebounded strongly over the last week, with the share price soaring 45...

  • Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test
    MarketWatch

    Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test

    Shares of Chembio Diagnostics Inc. skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S. exchanges, in the wake of the point-of-care diagnostics company's announcement of the commercial launch of its rapid COVID-19/flu test. The stock was on track for the biggest one-day percentage gain since it doubled, on March 12, 2004. Trading volume ballooned to 206.6 million shares, compared with the full-day average of less than 1 million shares. The company said its test has been granted emergency use authorization by the Food and Drug Administration. Chembio said after Thursday's closing bell that the product, which produces results in 15 minutes, requires no instrumentation and simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections, is immediately available for shipment. "As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources," said Charles Caso, vice president of sales and marketing at Chembio. The stock has run up 21.4% year to date, while the S&P 500 has gained 8.6%.

  • TheStreet.com

    Chembio Jumps on Launch of Test Distinguishing COVID, Flu

    Chembio launched a rapid test, cleared for emergency use by the FDA, that can differentiate between COVID-19 and influenza Type A and Type B.